Effects of dapagliflozin on cardiac function in patients with type 2 diabetes mellitus complicated with heart failure with preserved ejection fraction

ObjectiveTo study the effect of dapagliflozin on left ventricular ejection function and quality of life in patients with type 2 diabetes mellitus(T2DM) complicated with heart failure with preserved ejection fraction(HFpEF).

MethodsSeventy T2DM patients with HFpEF treated with insulin to reduce blood glucose were selected and randomly divided into observation group(n=38) and control group(n=32).The patients in the observation group were additionally treated with dapagliflozin to control the blood glucose, and patients in the control group were additionally treated with acarbose to control the blood glucose.The 6-minute walk test(6MWT) was used to evaluate the cardiac function of the patients, and the KCCQ questionnaire was applied to evaluate the quality of life of the patients.The 6MWT score, KCCQ score, left ventricular ejection fraction(LVEF), ventricular septal thickness, monocyte/high-density lipoprotein cholesterol ratio(MHR), N-terminal pro-B-type natriuretic peptide(NT-proBNP) and C-reactive protein(CRP) level were compared between the two groups before and after treatment.

ResultsAfter two months of treatment, the 6MWT score and MHR in the observation group were lower than those in the control group(P < 0.01 and P < 0.05), and there were no significant differences in the KCCQ score, ventricular septal thickness, LVEF, NT-proBNP and CRP levels between the two groups(P>0.05).After four months of treatment, the 6MWT score, MHR and CRP level in the observation group were lower than those in the control group(P < 0.05 to P < 0.01), the KCCQ score was higher than that in the control group(P < 0.05), and there were no significant differences in the ventricular septal thickness, LVEF and NT-proBNP level between the two groups(P>0.05).After six months of treatment, the KCCQ score and LVEF level in the observation group were higher than those in the control group(P < 0.05), the 6MWT score, MHR and CRP level were lower than those in the control group(P < 0.05 to P < 0.01), and there were no significant differences in the ventricular septal thickness and NT-proBNP level between the two groups(P>0.05).

ConclusionsDapagliflozin can improve the clinical symptoms and quality of life of T2DM patients with HFpEF.